ALK FUSION-POSITIVE SOLID OR CNS TUMORS
Clinical trials for ALK FUSION-POSITIVE SOLID OR CNS TUMORS explained in plain language.
Never miss a new study
Get alerted when new ALK FUSION-POSITIVE SOLID OR CNS TUMORS trials appear
Sign up with your email to follow new studies for ALK FUSION-POSITIVE SOLID OR CNS TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare cancers: alectinib trial launches
Disease control OngoingThis study tests the drug alectinib in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to other treatments or have no standard therapy. The goal is to see if alectinib is safe and can shrink or control these tumors.…
Matched conditions: ALK FUSION-POSITIVE SOLID OR CNS TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Scientists dig into the DNA of drug-resistant lung cancers to find hidden clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study enrolls 40 people with non-small cell lung cancer whose tumors have stopped responding to targeted therapy (tyrosine kinase inhibitors). Researchers will analyze the tumors' full genetic code and RNA to find new resistance mechanisms. The goal is to better understand w…
Matched conditions: ALK FUSION-POSITIVE SOLID OR CNS TUMORS
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC